Unpublished data may explain Lemtrada's efficacy...
Unpublished data may explain Lemtrada's efficacy...
Analysis of previously unpublished data from the pivotal phase III trials in the regulatory submissions of alemtuzumab, otherwise known as Lemtrada, indicated that efficiency was associated with long-term depletion of memory T- and B-cells. Whereas rapid hyper-repopulation of immature B-cells in the relative absence of regulatory CD4 and CD8 T-cells create the environment for the generation of secondary B-cell autoimmunity, including anti-drug antibodies...Read more - http://www.ms-uk.org/previously-unpubli ... cts-150617
-
- Similar Topics
- Replies
- Views
- Last post
-
-
how do i explain properly to a doctor whats going on
by albiet » Wed Feb 27, 2019 11:36 am » in Undiagnosed - 7 Replies
- 603 Views
-
Last post by NHE
Fri Mar 01, 2019 2:14 am
-
-
- 0 Replies
- 435 Views
-
Last post by Petr75
Sat Jan 05, 2019 3:10 am
-
-
Third course of Lemtrada improves MS patient’s relapse rate
by MSUK » Mon Mar 05, 2018 8:27 am » in Campath (Lemtrada, Alemtuzumab) - 0 Replies
- 2544 Views
-
Last post by MSUK
Mon Mar 05, 2018 8:27 am
-
-
-
Lemtrada (alemtuzumab) FDA issues risk of stroke warning
by Scott1 » Thu Nov 29, 2018 8:20 pm » in Campath (Lemtrada, Alemtuzumab) - 0 Replies
- 1965 Views
-
Last post by Scott1
Thu Nov 29, 2018 8:20 pm
-
-
-
Lemtrada (alemtuzumab) FDA issues risk of stroke warning
by Scott1 » Thu Nov 29, 2018 8:20 pm » in General Discussion - 0 Replies
- 1040 Views
-
Last post by Scott1
Thu Nov 29, 2018 8:20 pm
-
-
-
CCSVI reloaded. Brave Dreams data re-analysed.
by frodo » Sun Nov 24, 2019 5:39 am » in General Discussion - 1 Replies
- 100 Views
-
Last post by Petr75
Fri Nov 29, 2019 11:28 am
-